Idelalisib
Sign in to save this workspacePrimary targets: PI3K · FDA status: FDA Approved
Selectivity scorecard
KISS
100.00
Gini
0.701
CATDS
0.031
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Idelalisib. Strongest target: PKG2_PRKG2 at 27.4% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | PKG2_PRKG2 | 27.4% | 72.6% |
| 2 | PKN3_PRK3 | 18.6% | 81.4% |
| 3 | DRAK1_STK17A | 16.6% | 83.4% |
| 4 | BMPR2 | 15.6% | 84.4% |
| 5 | ERK2_MAPK1 | 15.4% | 84.6% |
| 6 | CAMK1B | 15.0% | 85.0% |
| 7 | RIPK4 | 12.1% | 87.9% |
| 8 | MLK3_MAP3K11 | 11.0% | 89.0% |
| 9 | MYO3A | 10.8% | 89.2% |
| 10 | OSR1_OXSR1 | 10.6% | 89.4% |
| 11 | FAK_PTK2 | 10.6% | 89.4% |
| 12 | PDGFRB | 10.6% | 89.4% |
| 13 | EPHB1 | 10.0% | 90.0% |
| 14 | PDK2_PDHK2 | 10.0% | 90.0% |
| 15 | MLK2_MAP3K10 | 10.0% | 90.0% |
| 16 | DAPK2 | 9.9% | 90.1% |
| 17 | BRK | 9.9% | 90.1% |
| 18 | STK25_YSK1 | 9.9% | 90.1% |
| 19 | DNA_PK | 9.5% | 90.5% |
| 20 | RIPK2 | 9.0% | 91.0% |
Selectivity landscape
Where Idelalisib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Idelalisib.
Atlas insights for Idelalisib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 181.77 | |
| ALLOGRAFT_REJECTION | 535.41 | |
| ANDROGEN_RESPONSE | 199.58 | |
| ANGIOGENESIS | 99.68 | |
| APICAL_JUNCTION | 647.35 | |
| APICAL_SURFACE | 99.36 | |
| APOPTOSIS | 642.13 | |
| BILE_ACID_METABOLISM | 69.77 | |
| CHOLESTEROL_HOMEOSTASIS | 98.42 | |
| COAGULATION | 89.27 | |
| COMPLEMENT | 377.37 | |
| DNA_REPAIR | 140.77 | |
| E2F_TARGETS | 499.21 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 188.37 | |
| ESTROGEN_RESPONSE_EARLY | 308.41 | |
| ESTROGEN_RESPONSE_LATE | 262.64 | |
| FATTY_ACID_METABOLISM | 46.29 | |
| G2M_CHECKPOINT | 468.00 | |
| GLYCOLYSIS | 233.02 | |
| HEDGEHOG_SIGNALING | 95.42 | |
| HEME_METABOLISM | 173.34 | |
| HYPOXIA | 401.36 | |
| IL2_STAT5_SIGNALING | 248.22 | |
| IL6_JAK_STAT3_SIGNALING | 293.04 | |
| INFLAMMATORY_RESPONSE | 309.99 | |
| INTERFERON_ALPHA_RESPONSE | 70.22 | |
| INTERFERON_GAMMA_RESPONSE | 366.91 | |
| KRAS_SIGNALING_DN | 124.53 | |
| KRAS_SIGNALING_UP | 210.02 | |
| MITOTIC_SPINDLE | 548.28 | |
| MTORC1_SIGNALING | 374.14 | |
| MYC_TARGETS_V1 | 363.54 | |
| MYC_TARGETS_V2 | 100.54 | |
| MYOGENESIS | 278.29 | |
| NOTCH_SIGNALING | 33.26 | |
| OXIDATIVE_PHOSPHORYLATION | 122.14 | |
| P53_PATHWAY | 349.09 | |
| PANCREAS_BETA_CELLS | 43.12 | |
| PEROXISOME | 71.68 | |
| PI3K_AKT_MTOR_SIGNALING | 706.36 | |
| PROTEIN_SECRETION | 173.03 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 37.73 | |
| SPERMATOGENESIS | 160.65 | |
| TGF_BETA_SIGNALING | 162.54 | |
| TNFA_SIGNALING_VIA_NFKB | 355.77 | |
| UNFOLDED_PROTEIN_RESPONSE | 146.53 | |
| UV_RESPONSE_DN | 357.55 | |
| UV_RESPONSE_UP | 290.09 | |
| WNT_BETA_CATENIN_SIGNALING | 204.98 | |
| XENOBIOTIC_METABOLISM | 180.82 |
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.864 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.844 |
| SRR23303752 | — | 0.838 |
| SRR12202498 | — | 0.830 |
| C3N-03420 | — | 0.829 |
Annotations
Sign in to read and post annotations.
Loading…